Atlas Trials

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Clinical trial NCT03704077 · WITHDRAWN

Trial details

NCT number
NCT03704077
Sponsor
Bristol-Myers Squibb
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Gastric CancerCancer of the StomachStomach CancerGastroesophageal Junction
Start date
2019-10-31
Primary completion
2022-02-27
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.